PT-150 is under clinical development by Palisades Therapeutics and currently in Phase II for Opium (Opioid) Addiction. According to GlobalData, Phase II drugs for Opium (Opioid) Addiction have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PT-150’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PT-150 is under development for the treatment of opiod nicotine addiction, alcohol addiction, pancreatic cancer, glioblastoma, treatment-resistant prostate cancer, ovarian cancer, TNBC and Covid-19. It acts by targeting GR translocation and corticosterone-induced GR translocation. It was also under development for the treatment of psychotic major depression, breast cancer and ovarian cancer. The drug candidate in combination with chemo therapeutics used as a chemo sensetizer.
For a complete picture of PT-150’s drug-specific PTSR and LoA scores, buy the report here.